Literature DB >> 6544898

Plasma pharmacokinetics of adriamycin after intrapleural administration.

S Eksborg, A Lindfors, B J Cedermark.   

Abstract

The plasma pharmacokinetics of adriamycin after intrapleural administration have been studied. The maximum plasma concentration found after intrapleural instillation of 50 mg was 100 ng ml-1, the adriamycin half-life being about 2.5 h. Large amounts of the drug are adsorbed from the pleura. Hence risks for cardiomyopathy, previously associated with the repeated intravenous administration of adriamycin, must also be considered after intrapleural administration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6544898     DOI: 10.1007/bf02934140

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  14 in total

1.  Adriamycin-a review.

Authors:  S K Carter
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

2.  Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder.

Authors:  M D Banks; J E Pontes; R M Izbicki; J M Pierce
Journal:  J Urol       Date:  1977-11       Impact factor: 7.450

3.  Cardiotoxicity of adriamycin and related anthracyclines.

Authors:  L Lenaz; J A Page
Journal:  Cancer Treat Rev       Date:  1976-09       Impact factor: 12.111

4.  Intracavitary doxorubicin in malignant effusions.

Authors:  M H Tattersall; R M Fox; E S Newlands; R L Woods
Journal:  Lancet       Date:  1979-02-17       Impact factor: 79.321

5.  Intracavitary adriamycin nitrogen mustard and tetracycline in the control of malignant effusions: a randomized study.

Authors:  R F Kefford; R L Woods; R M Fox; M H Tatterall
Journal:  Med J Aust       Date:  1980-10-18       Impact factor: 7.738

6.  Studies on the intravesical action of topically administered G3H-doxorubicin hydrochloride in men: plasma uptake and tumor penetration.

Authors:  G H Jacobi; K H Kurth
Journal:  J Urol       Date:  1980-07       Impact factor: 7.450

7.  [Bladder instillation of adriamycin in the treatment of bladder tumors. Report 1: Clinical results (author's transl)].

Authors:  Y Ozaki
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1977-10

8.  Adriamycin cardiotoxicity: a survey of 1273 patients.

Authors:  C Praga; G Beretta; P L Vigo; G R Lenaz; C Pollini; G Bonadonna; R Canetta; R Castellani; E Villa; C G Gallagher; H von Melchner; M Hayat; P Ribaud; G De Wasch; W Mattsson; R Heinz; R Waldner; K Kolaric; R Buehner; W Ten Bokkel-Huyninck; N I Perevodchikova; L A Manziuk; H J Senn; A C Mayr
Journal:  Cancer Treat Rep       Date:  1979-05

9.  Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol.

Authors:  S Eksborg; H Ehrsson; I Andersson
Journal:  J Chromatogr       Date:  1979-12-01

10.  Adriamycin cardiomyopathy--risk factors.

Authors:  R A Minow; R S Benjamin; E T Lee; J A Gottlieb
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860

View more
  1 in total

Review 1.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.